RS62295B1 - Farmaceutskе kompozicijе kojе sadržе insulin - Google Patents

Farmaceutskе kompozicijе kojе sadržе insulin

Info

Publication number
RS62295B1
RS62295B1 RS20211060A RSP20211060A RS62295B1 RS 62295 B1 RS62295 B1 RS 62295B1 RS 20211060 A RS20211060 A RS 20211060A RS P20211060 A RSP20211060 A RS P20211060A RS 62295 B1 RS62295 B1 RS 62295B1
Authority
RS
Serbia
Prior art keywords
pharmaceutical compositions
containing pharmaceutical
insulin containing
insulin
compositions
Prior art date
Application number
RS20211060A
Other languages
English (en)
Inventor
Mathias Norrman
Susanne Hostrup
Dorte Bjerre Steensgaard
Holger Martin Strauss
Rosa Rebecca Erritzøe Hansen
Svend Havelund
Morten Schlein
Jesper Søndergaard Pedersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of RS62295B1 publication Critical patent/RS62295B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Manipulator (AREA)
RS20211060A 2016-12-16 2017-12-15 Farmaceutskе kompozicijе kojе sadržе insulin RS62295B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16204688 2016-12-16
EP17832941.3A EP3554534B1 (en) 2016-12-16 2017-12-15 Insulin containing pharmaceutical compositions
PCT/EP2017/083013 WO2018109162A1 (en) 2016-12-16 2017-12-15 Insulin containing pharmaceutical compositions

Publications (1)

Publication Number Publication Date
RS62295B1 true RS62295B1 (sr) 2021-09-30

Family

ID=57570394

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20211060A RS62295B1 (sr) 2016-12-16 2017-12-15 Farmaceutskе kompozicijе kojе sadržе insulin
RS20221009A RS63773B1 (sr) 2016-12-16 2017-12-15 Farmaceutske kompozicije koje sadrže insulin

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20221009A RS63773B1 (sr) 2016-12-16 2017-12-15 Farmaceutske kompozicije koje sadrže insulin

Country Status (28)

Country Link
US (5) US20180169190A1 (sr)
EP (2) EP3554534B1 (sr)
JP (2) JP6690062B2 (sr)
KR (2) KR102374354B1 (sr)
CN (2) CN110087674B (sr)
AU (2) AU2017378102B2 (sr)
BR (1) BR112019011761A2 (sr)
CA (1) CA3046583A1 (sr)
CL (1) CL2019001586A1 (sr)
CO (1) CO2019006017A2 (sr)
DK (2) DK3554534T3 (sr)
ES (2) ES2886837T3 (sr)
HR (2) HRP20221324T1 (sr)
HU (2) HUE055231T2 (sr)
IL (2) IL300839B2 (sr)
MA (1) MA49116A (sr)
MX (2) MX2019006463A (sr)
MY (1) MY194504A (sr)
PE (2) PE20210857A1 (sr)
PH (1) PH12019501363A1 (sr)
PL (2) PL3821905T3 (sr)
PT (1) PT3554534T (sr)
RS (2) RS62295B1 (sr)
RU (1) RU2758367C2 (sr)
SA (2) SA519401933B1 (sr)
SI (1) SI3554534T1 (sr)
TW (2) TWI700091B (sr)
WO (1) WO2018109162A1 (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2910569B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
JP6690062B2 (ja) * 2016-12-16 2020-04-28 ノヴォ ノルディスク アー／エス インスリン含有医薬組成物
TW202039539A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 具有經降低胰島素受體結合親和力的胰島素類似物
WO2021116243A1 (en) 2019-12-10 2021-06-17 Sanofi A method of forming a conjugate of a sulfonamide and a polypeptide
EP4086279A4 (en) * 2019-12-30 2024-08-07 Gan & Lee Pharmaceuticals Co Ltd INSULIN DERIVATIVE
JP7424918B2 (ja) * 2020-06-18 2024-01-30 株式会社平和 遊技機
CN118139875A (zh) * 2021-06-25 2024-06-04 甘李药业股份有限公司 含酰化胰岛素的药物组合物
JP7437833B1 (ja) 2023-09-21 2024-02-26 俊二 二宮 検体検査用のカラー濾紙及びその製造方法

Family Cites Families (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832685A (en) 1952-05-24 1958-04-29 Crest Foods Co Inc Solubilization of milk proteins
GB894095A (en) 1960-02-08 1962-04-18 Tanaka Shoichi A therapeutic device for personal wear
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3719655A (en) 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033941A (en) 1975-12-17 1977-07-05 Eli Lilly And Company Process for purifying glucagon
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS6030650B2 (ja) 1979-10-26 1985-07-17 日本油脂株式会社 座薬基剤組成物
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
US5266310A (en) 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
KR900701842A (ko) 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5225323A (en) 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
ATE120762T1 (de) 1989-04-20 1995-04-15 Sinai School Medicine Hepatospezifische insulin-analoga.
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1991003935A1 (en) 1989-09-22 1991-04-04 Tsi-Mason Research Institute Method and compositions for one-step cryopreservation of embryos
KR930001305B1 (ko) 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type)
US5179189A (en) 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
DK45590D0 (sr) 1990-02-21 1990-02-21 Novo Nordisk As
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK158390D0 (da) 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
AU8091091A (en) 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
EP0548238A1 (en) 1990-09-13 1993-06-30 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
EP0952855B1 (en) 1991-07-03 2005-07-27 Meditech Research Limited Use of hyaluronan in gene therapy
PT100726A (pt) 1991-07-26 1993-09-30 Smithkline Beecham Corp Microemulsoes de agua em oleo, auto-emulsionantes, estaveis e farmaceuticamente aceitaveis e seu uso
US5268453A (en) 1991-08-08 1993-12-07 Scios Inc. Tissue-selective insulin analogs
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
ZA928916B (en) 1991-11-26 1994-05-18 Lilly Co Eli Tri-arginine insulins
DE59208181D1 (de) 1991-12-18 1997-04-17 Hoechst Ag Verfahren zur Gewinnung von insulinhaltigen Lösungen
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
EP0671929A4 (en) 1992-10-16 1996-09-25 Smithkline Beecham Corp COMPOSITIONS.
WO1994008605A1 (en) 1992-10-16 1994-04-28 Smithkline Beecham Corporation Therapeutic microemulsions
EP0684833A4 (en) 1993-02-17 1996-09-11 Smithkline Beecham Corp MICRO-EMULSIONS COMPRISING THERAPEUTIC PEPTIDES.
WO1994019003A1 (en) 1993-02-17 1994-09-01 Smithkline Beecham Corporation Microemulsions comprising therapeutic peptides
EP0686045B1 (en) 1993-02-23 2000-11-15 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
UA45321C2 (uk) 1993-09-17 2002-04-15 Ново Нордіск А/С Похідне інсуліну, фармацевтична композиція для лікування діабету та спосіб лікування діабету
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
GB9323588D0 (en) 1993-11-16 1994-01-05 Cortecs Ltd Hydrophobic preparation
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
GB2296712B (en) 1995-01-05 1999-02-24 British Gas Plc Absorbents for separating nitrogen from a feed gas
EP0871665B1 (en) 1995-03-17 2003-07-23 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US20010041786A1 (en) 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
WO1997002043A1 (en) 1995-06-30 1997-01-23 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
US20030104981A1 (en) 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
AU3255397A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
PT938502E (pt) 1996-07-11 2005-02-28 Novo Nordisk As Metodo selectivo por acilacao
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
ATE264871T1 (de) 1996-07-26 2004-05-15 Aventis Pharma Gmbh Insulinderivate mit erhöhter zinkbindung
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6160541A (en) 1997-01-21 2000-12-12 Lear Automotive Dearborn Inc. Power consumption control for a visual screen display by utilizing a total number of pixels to be energized in the image to determine an order of pixel energization in a manner that conserves power
GB2355195B (en) 1997-01-30 2001-09-12 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
EP1025125B1 (en) 1997-10-24 2003-06-25 Novo Nordisk A/S Aggregates of human insulin derivatives
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
KR20010024556A (ko) 1997-10-24 2001-03-26 피터 지. 스트링거 불용성 인슐린 조성물
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
CA2334859A1 (en) 1998-06-12 1999-12-23 Kings College London Insulin analogue
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
CA2341624C (en) 1998-08-25 2008-12-02 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7030083B2 (en) 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
KR100617286B1 (ko) 1998-10-16 2006-08-30 노보 노르디스크 에이/에스 폐 송달을 위한 안정한 농축 인슐린 조제물
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
ATE220917T1 (de) 1999-01-26 2002-08-15 Lilly Co Eli Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2000061178A1 (en) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
CA2370302A1 (en) 1999-04-27 2000-11-02 Benjamin Lee Hughes Insulin crystals for pulmonary administration
US6746853B1 (en) 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
JP2003518917A (ja) 1999-05-19 2003-06-17 ゼンコー 糖尿病の処置に有用なインシュリン様活性を有する新規タンパク質
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
AU5453300A (en) 1999-06-29 2001-01-31 Eli Lilly And Company Insulin crystals for pulmonary administration
AU777570B2 (en) 1999-12-16 2004-10-21 Eli Lilly And Company Polypeptide compositions with improved stability
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
AU4935701A (en) 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
WO2001092334A1 (en) 2000-06-02 2001-12-06 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
CN1141974C (zh) 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
SK15532003A3 (sk) 2001-05-21 2004-06-08 Nektar Therapeutics Prípravok inzulínu na pľúcne podávanie
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
EP1430082B1 (en) 2001-09-07 2009-10-28 Biocon Limited Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
US8535650B2 (en) 2001-12-03 2013-09-17 Soligenix, Inc. Stabilized reverse micelle compositions and uses thereof
WO2003050276A1 (en) 2001-12-05 2003-06-19 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
WO2003053460A1 (en) 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
IL161848A0 (en) 2001-12-20 2005-11-20 Lilly Co Eli Insulin moldecule having protracted time action
UA46669C2 (uk) 2001-12-29 2005-12-15 Товариство З Обмеженою Відповідальністю "Мако" Спосіб приготування готової лікарської форми інсуліну пролонгованої дії
AU2003208316A1 (en) 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
EP1506003A1 (en) 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
WO2003094956A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN1165549C (zh) 2002-06-15 2004-09-08 江苏万邦生化医药股份有限公司 胰岛素的纯化方法
EP1545526A4 (en) 2002-09-17 2009-09-23 Merck & Co Inc ELIMINATION OF AN ALDEHYDE IMPURITY IN A REACTIVE POLYSTYRENE RESIN
US20050065066A1 (en) * 2002-12-20 2005-03-24 Kaarsholm Niels Christian Stabilised insulin compositions
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
US20040185068A1 (en) 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
EP2292253A3 (en) 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN1836047B (zh) 2003-06-17 2010-12-22 赛姆生物系统遗传公司 在植物中生产胰岛素的方法
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
EP1648933B1 (en) 2003-07-25 2009-06-17 ConjuChem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
PL2107069T3 (pl) 2003-08-05 2013-06-28 Novo Nordisk As Nowe pochodne insuliny
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
AU2004264958B2 (en) 2003-08-13 2010-04-15 Biocon, Ltd Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
MXPA06005581A (es) 2003-11-20 2006-08-11 Novo Nordisk As Formulaciones de peptidos que contienen propilenglicol que son optimas para la produccion y uso en dispositivos de inyeccion.
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
DE10358387A1 (de) 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
CN101084016A (zh) 2004-04-15 2007-12-05 克艾思马有限公司 能够容易穿透生物学障碍的组合物
AU2005247369A1 (en) 2004-05-10 2005-12-08 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
JP2008505866A (ja) 2004-07-09 2008-02-28 ノボ　ノルディスク　アクティーゼルスカブ インスリンを含有する薬学的製剤
CA2580313C (en) 2004-07-19 2016-03-15 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
AU2005273968A1 (en) 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
EP1814530A2 (en) 2004-09-27 2007-08-08 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule-formulations
US8263551B2 (en) * 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
ES2540754T3 (es) 2004-12-03 2015-07-13 Rhode Island Hospital Diagnóstico y tratamiento de la Enfermedad de Alzheimer
WO2006079641A2 (en) 2005-01-27 2006-08-03 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
ES2490243T3 (es) 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
US20090123563A1 (en) 2005-02-07 2009-05-14 Novo Nordisk A/S Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20100216690A1 (en) 2005-03-18 2010-08-26 Novo Nordisk A/S Pegylated Single-Chain Insulin
WO2006103657A2 (en) 2005-03-31 2006-10-05 Dexcel Pharma Technologies Ltd. A solid composition for intra-oral delivery of insulin
WO2006110551A2 (en) 2005-04-08 2006-10-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
CN101180081B (zh) 2005-05-25 2015-08-26 诺沃-诺迪斯克有限公司 稳定的多肽制剂
WO2007006320A1 (en) 2005-07-12 2007-01-18 Sherine Hassan Abbas Helmy Drinkable oral insulin liquid and capsules
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
JP4710533B2 (ja) 2005-10-07 2011-06-29 株式会社豊田自動織機 牽引車両のドローバー装置
CA2626357A1 (en) 2005-10-20 2007-04-26 Nastech Pharmaceutical Company Inc. Intranasal administration of rapid acting insulin
DK1969004T3 (da) * 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
EP1996709A2 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
ES2548393T3 (es) 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
JP5269766B2 (ja) 2006-05-09 2013-08-21 ノボ・ノルデイスク・エー／エス インスリン誘導体
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
KR101699370B1 (ko) 2006-09-22 2017-02-14 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
EP2152243A2 (en) 2007-04-30 2010-02-17 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2514407A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
CN101743252A (zh) 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、peg化的胰岛素类似物
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
KR20100053561A (ko) 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US20090087484A1 (en) 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
MX2010005245A (es) * 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
EP2910569B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2010060667A1 (en) 2008-11-28 2010-06-03 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
US20110294729A1 (en) 2008-12-09 2011-12-01 Novo Nordisk A/S Novel Insulin Analogues
CA2752437C (en) * 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
EP2477644A1 (en) 2009-09-16 2012-07-25 Novo Nordisk A/S Stable non-aqueous liquid pharmaceutical compositions comprising an insulin
CN102665676B (zh) * 2009-11-02 2015-04-01 诺沃-诺迪斯克有限公司 非共价结合的白蛋白和酰化胰岛素的药物溶液
AU2011206629B2 (en) 2010-01-12 2014-07-17 Novo Nordisk A/S Pharmaceutical compositions for oral administration of insulin peptides
JP5931857B2 (ja) 2010-06-23 2016-06-08 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するインスリン誘導体
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
CN103154024A (zh) 2010-10-15 2013-06-12 诺沃—诺迪斯克有限公司 新型n末端修饰的胰岛素衍生物
CN103249427A (zh) * 2010-12-14 2013-08-14 诺沃—诺迪斯克有限公司 速效胰岛素联合长效胰岛素
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
JP6199956B2 (ja) * 2012-04-11 2017-09-20 ノヴォ ノルディスク アー／エス インスリン製剤
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CN105324126A (zh) 2013-06-21 2016-02-10 诺和诺德股份有限公司 Glp-1受体激动剂在用胰岛素治疗的和/或患有1型糖尿病的患者中的新用途
BR112016007166A2 (pt) * 2013-10-07 2017-09-12 Novo Nordisk As derivado de um análogo de insulina
CN104587455A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种胰岛素制剂
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
MX2016008978A (es) * 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
US20170028031A1 (en) 2014-03-07 2017-02-02 Klavs Holger Jørgensen Novel fast acting insulin preparations
TWI685348B (zh) 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JP6690062B2 (ja) 2016-12-16 2020-04-28 ノヴォ ノルディスク アー／エス インスリン含有医薬組成物

Also Published As

Publication number Publication date
IL300839B2 (en) 2024-04-01
HRP20221324T1 (hr) 2022-12-23
CN115154591A (zh) 2022-10-11
US20180169190A1 (en) 2018-06-21
RU2019118696A3 (sr) 2021-03-19
WO2018109162A1 (en) 2018-06-21
SA519401933B1 (ar) 2024-01-25
MX2021002083A (es) 2021-04-28
PH12019501363A1 (en) 2020-02-24
JP6788139B2 (ja) 2020-11-18
IL300839A (en) 2023-04-01
TW201827071A (zh) 2018-08-01
PE20191205A1 (es) 2019-09-10
TWI700091B (zh) 2020-08-01
EP3821905B1 (en) 2022-10-12
US20180303908A1 (en) 2018-10-25
MX2019006463A (es) 2019-08-14
CN115154591B (zh) 2023-04-14
EP3554534A1 (en) 2019-10-23
JP2020502145A (ja) 2020-01-23
EP3554534B1 (en) 2021-06-23
US10596231B2 (en) 2020-03-24
JP6690062B2 (ja) 2020-04-28
CL2019001586A1 (es) 2019-08-16
IL300839B1 (en) 2023-12-01
CA3046583A1 (en) 2018-06-21
EP3821905A1 (en) 2021-05-19
KR102580007B1 (ko) 2023-09-19
CO2019006017A2 (es) 2019-10-31
IL267224A (en) 2019-08-29
DK3554534T3 (da) 2021-08-23
ES2886837T3 (es) 2021-12-21
HUE060149T2 (hu) 2023-02-28
MY194504A (en) 2022-11-30
US20200384088A1 (en) 2020-12-10
CN110087674B (zh) 2023-01-03
BR112019011761A2 (pt) 2019-11-05
TWI700092B (zh) 2020-08-01
US20190183979A1 (en) 2019-06-20
KR20190097001A (ko) 2019-08-20
PL3821905T3 (pl) 2022-12-27
PT3554534T (pt) 2021-11-05
RS63773B1 (sr) 2022-12-30
AU2022218612A1 (en) 2022-09-22
IL267224B2 (en) 2023-10-01
TW202003017A (zh) 2020-01-16
SA520420276B1 (ar) 2022-12-05
MA49116A (fr) 2020-03-25
CN110087674A (zh) 2019-08-02
AU2017378102A1 (en) 2019-05-30
SI3554534T1 (sl) 2021-09-30
PE20210857A1 (es) 2021-05-18
AU2017378102B2 (en) 2022-10-13
AU2022218612B2 (en) 2024-03-07
PL3554534T3 (pl) 2021-12-13
RU2019118696A (ru) 2021-01-18
IL267224B1 (en) 2023-06-01
RU2758367C2 (ru) 2021-10-28
US20220202909A1 (en) 2022-06-30
HRP20211281T1 (hr) 2021-11-12
US10265385B2 (en) 2019-04-23
JP2020105227A (ja) 2020-07-09
KR20210091350A (ko) 2021-07-21
DK3821905T3 (da) 2022-11-14
ES2930149T3 (es) 2022-12-07
HUE055231T2 (hu) 2021-11-29
KR102374354B1 (ko) 2022-03-15

Similar Documents

Publication Publication Date Title
IL265360A (en) Pharmaceutical composition
IL265260B (en) pharmaceutical preparations
IL267224A (en) Pharmaceutical preparations containing insulin
IL262654A (en) Pharmacy preparation
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
IL265349A (en) Pharmaceutical composition
LT3278801T (lt) Farmacinė kompozicija, turinti mirabegrono
IL263040A (en) Pharmaceutical composition comprising eteplirsen
GB201521462D0 (en) Pharmaceutical composition
IL267136A (en) Pharmaceutical composition containing celecoxib
GB201615917D0 (en) Pharmaceutical composition
HK1250491A1 (zh) 穩定化的醫藥組合物
GB201515310D0 (en) Pharmaceutical composition
PL3454838T3 (pl) Kompozycja farmaceutyczna
GB201615914D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
ZA201500995B (en) Low dose pharmaceutical composition
IL265436B (en) Pharmacy preparation
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
GB201620519D0 (en) Pharmaceutical composition
IL265428A (en) Pharmaceutical composition
PT3476391T (pt) Composição farmacêutica que compreende arginina para utilização no tratamento da doença de poliq
IL253572A0 (en) A liquid pharmaceutical preparation
GB201620516D0 (en) Pharmaceutical composition